Diffregen Overview
- Founded
- 2011
- Status
- Private
- Latest Deal Type
- Accelerator/Inc
- Investors
- 3
Diffregen General Information
Description
Developer of therapeutics designed to stop the progression of cancer and activate the healthy immune system. The company's services uses active ingredients are based on Angiocidin, a protein which has been shown to activate monocytes and drive terminal differentiation of leukemia cells, enabling AML patients to get proper treatement against cancer.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare
Primary Office
- 440 Coldstream Drive
- PA 19312
- United States
Diffregen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Accelerator/Incubator | 21-Feb-2018 | Completed | Startup | |||
| 2. Grant | 01-Jan-2013 | 00000 | Completed | Startup | ||
| 1. Grant | 01-Jan-2011 | $100K | Completed | Startup |
Diffregen Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Deni Zodda | Chief Executive Officer | ||
| George Tuszynski Ph.D | Founder |
Diffregen Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| MassChallenge | Accelerator/Incubator | 000 0000 | 000000 0 | ||
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
| Science Center | Accelerator/Incubator | 000 0000 | 000000 0 |